| 1 |
31545160 | Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus. | 2020 Mar |
1 |
| 2 |
29185859 | Burden of Rifampicin- and Methicillin-Resistant Staphylococcus aureus in Italy. | 2018 Jul/Aug |
1 |
| 3 |
28139739 | Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. | 2017 Jan 31 |
2 |
| 4 |
24957836 | Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus. | 2014 Sep |
2 |
| 5 |
23113753 | Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection. | 2013 Mar |
2 |
| 6 |
21822974 | Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis. | 2012 May |
1 |
| 7 |
22253738 | Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. | 2012 |
2 |
| 8 |
20598637 | Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. | 2010 Oct |
2 |
| 9 |
19387707 | Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. | 2009 Aug |
2 |
| 10 |
16940100 | Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. | 2006 Sep |
2 |